HedgePath reports positive interim data from Phase IIb trial of SUBA-Itraconazole to treat Gorlin Syndrome
US-based, clinical stage biopharmaceutical company HedgePath (HPPI) has reported positive interim data from its Phase IIb clinical trial of SUBA-Itraconazole to treat basal cell carcinoma nevus syndrome (BCCNS), also known as Gorlin Syndrome.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Basal Cell Carcinoma | Cancer & Oncology | Carcinoma | Clinical Trials | Gorlin syndrome | Pharmaceuticals | Skin Cancer